 Shares of Teva Pharmaceutical Industries Ltd. TEVA, -2.01 shed 1.2 in premarket trading Wednesday, after the Israel-based generic drug maker reported fourth-quarter profit that topped expectations but revenue that missed, as COVID-19 continued to impact patient behavior and prescribing patterns. 